Clinical Core

核心B：临床核心总结/摘要： 阿尔茨海默病（AD）的诊断、治疗和预防的进展关键取决于 从正常到临床前过渡的大型"试验就绪"受试者队列的可用性 AD分期，轻度认知障碍（MCI），至早期AD。PITT-ADRC临床核心有效地 完成了这一点，评估了自成立以来超过4700名参与者的队列，并提供了 参与者、生物样本和大量研究的数据，这些研究严重依赖于不同的临床 人群：有AD风险的参与者（例如预防、生物标志物研究）;临床AD参与者（例如 AD的GWAS、精神病的GWAS）;尸检证实的AD受试者（例如，尸检组织研究）; 以及患有其他痴呆症的参与者（例如DLB联盟）。临床核心已经开发出方法， 最大限度地灵活地满足这些多样化和不断变化的支助调查的需要。在 除了作为PITT-ADRC中许多资助研究的关键资源外，临床核心还将提供 参与者将作为神经影像学核心和生物标志物评价的重点 神经遗传学核心在本报告所述期间，我们还保持了 所有参与者的神经精神病学特征，并进一步提高了我们的尸检同意率，支持 神经病理学核心和多个附属R01。我们继续保持良好的记录， 每年收集大量参与者的遗传样本和数据，用于地方R01和国家和 国际财团。最后，我们增加了具有帕金森病专业知识的新研究人员 综合征和FTLD，并开发了新的程序，以增加完成随访的比率， 我们的参与者这些成就为临床核心做好了准备， 以下一组拟议的具体目的：1）在研究入组时和年度随访时进行评价 参与PITT-ADRC的正常对照、MCI前、MCI、AD和相关痴呆参与者; 2） 确保最大限度地参与临床、干预、脑成像、生物标志物和尸检研究， 在纵向随访期间提供适当的研究转诊和临床服务; 3）提供 临床数据、研究参与者、DNA样本以及技术和科学领导力，以支持新的和 正在进行的研究项目在PITT-ADRC，内部和外部匹兹堡大学，并支持 国家联盟研究; 4）与外联，招聘和参与核心合作， 促进招募和留住不同的参与者; 5）支持研究和教育 通过提供研究参与者，样本， 和数据

Core B: Clinical Core Summary/Abstract: Progress in the diagnosis, treatment, and prevention of Alzheimer’s Disease (AD) depends critically on the availability of large “trial-ready” cohorts of participants spanning the transition from normal through preclinical AD stages, mild cognitive impairment (MCI), to early AD. The PITT-ADRC Clinical Core has effectively accomplished this, evaluating a cohort of more than 4700 participants since its inception and providing participants, biologic samples, and data for a wide array of studies that depend critically on differing clinical populations: participants at risk for AD (e.g. prevention, biomarker studies); participants with clinical AD (e.g. GWAS of AD, GWAS of psychosis); participants with autopsy-confirmed AD (e.g. postmortem-tissue studies); and participants with other dementias (e.g. DLB consortium). The Clinical Core has developed approaches to maximize flexibility in meeting the needs of these diverse, and evolving, set of supported investigations. In addition to its role as a critical resource for many funded studies in the PITT-ADRC, the Clinical Core will provide participants that will serve as a focus for biomarker evaluation by the Neuroimaging Core and the Biomarker and Neurogenetics Core. During the current period we have also maintained our strong history of neuropsychiatric characterization of all participants and further enhanced our rate of autopsy consent, supporting the Neuropathology Core and multiple affiliated R01s. We have continued our strong record of providing genetic samples and data on large numbers of participants annually for use in local R01s and in national and international consortia. Finally, we have added new investigators with specialized expertise in Parkinsonian syndromes and FTLD and have developed new procedures to increase the rate of completed follow-up visits for our participants. These accomplishments have prepared the Clinical Core to maintain its productivity in the following set of proposed Specific Aims: 1) To perform evaluations at study entry and at annual follow-up of Normal Control, pre-MCI, MCI, AD, and related dementia participants participating in the PITT-ADRC; 2) To assure maximum participation in clinical, intervention, brain imaging, biomarker, and autopsy studies by providing appropriate research study referrals and clinical services during longitudinal follow-up; 3) To provide clinical data, research participants, DNA samples, and technical and scientific leadership to support new and ongoing research projects at the PITT-ADRC, within and outside the University of Pittsburgh, and to support national consortium studies; 4) In collaboration with the Outreach, Recruitment, and Engagement Core, to facilitate recruitment and retention of diverse participants; 5) To support the Research and Education Component in training the next generation of dementia researchers by providing research participants, samples, and data.